Trial Profile
A Phase 3, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study of NRP104 in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors New River Pharmaceuticals
- 10 Jul 2019 According to a Takeda media release, Health Canada's authorization of VYVANSE capsules in children aged 6-12 years with ADHD was based on two, 4-week, clinical studies(NRP104-301 and NRP104-201)
- 12 Nov 2009 Results from a post hoc analysis (of emotional lability) were presented at a scientific meeting, according to a Shire media release
- 20 Nov 2007 New trial record.